Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Videos|November 25, 2013
Crizotinib in ALK-Positive Lung Cancer
Author(s)Alice T. Shaw, MD, PhD
Alice T. Shaw, MD, PhD, discusses using crizotinib to treat patients with ALK-positive lung cancer.
Advertisement
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses using crizotinib to treat patients with ALK-positive lung cancer.
Clinical Pearls:
- Now that crizotinib is an FDA-approved agent, it is viewed as standard of care treatment for patients with ALK-positive lung cancer
- A study showed that crizotinib is superior to chemotherapy in patients with ALK-positive lung cancer in the second-line setting
- NCCN recommends testing patients with non-squamous lung cancer forEGFRandALKmutations
- The results of a trial that compares crizotinib to frontline chemotherapy should be ready sometime next year
Advertisement
Related to this article
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Upfront Surgery Vs Total Neoadjuvant Therapy in Rectal Cancer
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5